Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.41 |
| ▸ | OGA | O60502 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | NPY1R | P25929 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HRH2 | P25021 | 3/20 | 0.38 |
| ▸ | HRH1 | P35367 | 3/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | CCR3 | P51677 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19600802 | 0.95 | HRH3 (0.42) | HRH3P2RY12DGAT1OGANPY1R | |
| SCHEMBL19601071 | 0.91 | HRH3 (0.47) | HRH3P2RY12DGAT1OGALMNA | |
| SCHEMBL19580877 | 0.87 | HRH3 (0.44) | HRH3P2RY12DGAT1DRD2HTR2A | |
| SCHEMBL19598752 | 0.87 | PPARG (0.45) | HRH3P2RY12DGAT1DRD2HTR2A | |
| SCHEMBL19580786 | 0.86 | P2RY12 (0.49) | HRH3P2RY12DGAT1DRD2HTR2A | |
| SCHEMBL19600720 | 0.83 | HRH3 (0.48) | HRH3P2RY12DGAT1OGALMNA | |
| SCHEMBL19580779 | 0.82 | USP30 (0.42) | HRH3P2RY12DGAT1DRD2HTR2A | |
| SCHEMBL19581133 | 0.81 | P2RY12 (0.46) | HRH3P2RY12LMNA | |
| SCHEMBL19600800 | 0.81 | HRH3 (0.49) | HRH3P2RY12DGAT1OGALMNA | |
| SCHEMBL19598769 | 0.78 | HRH3 (0.46) | HRH3P2RY12USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, MDM2, ESRRA | HRH3 3784/4885P2RY12 4874/4885DGAT1 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.